1. Pink Sheet
  2. >>R&D

Amicus Pompe Disease Combo’s Approvability In Question As Key Trial Misses Mark

Company Touts ‘Totality Of Data’ As Supporting Approval

 
• By Alaric DeArment

The company hopes to score a nod from the US FDA based on a secondary endpoint that won approval for Sanofi’s Lumizyme.

Render illustration of Clinical Trial title on medical documents
Amicus' Phase III study of AT-GAA in Pompe disease failed to meet its primary endpoint, raising questions about the combination's approval prospects. • Source: Shutterstock

Amicus Therapeutics, Inc.’s cipaglucosidase alfa/miglustat for late-onset Pompe disease (LOPD) may be a tough sell for regulators after its pivotal Phase III trial failed to meet its primary endpoint. Mostly – though not entirely – successful numbers on a key secondary endpoint may present a path forward. But even if it does win approval, it could face limited commercial prospects.

Philadelphia-based Amicus announced 11 February results from the Phase III PROPEL study comparing the two-component therapy – known as AT-GAA – against Sanofi’s enzyme-replacement therapy (ERT) Lumizyme (alglucosidase alfa). The study’s primary endpoint was six-minute walk distance (6MWD) at 52 weeks across the combined population of patients who switched from Lumizyme and those who were ERT-naïve

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 
• By Anabel Costa-Ferreira

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 
• By Eliza Slawther

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.

Pharma Industry Argues Tax, Other Incentives Better Than Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a federal 232 investigation.

US FDA Guidance Roadblock: Writing Continues, But Publication Has Slowed Or Stopped

 
• By Derrick Gingery

Cuts to the FDA’s policy and legal personnel have prevented dozens of product-specific guidances for generic drug development from being published.

More from Pink Sheet

Recent and Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 
• By Anabel Costa-Ferreira

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 
• By Eliza Slawther

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.